title: Expression of Bcl-2 in olfactory neuroblastoma and its association with chemotherapy and survival.
abstract: OBJECTIVE
  This study aimed to identify the prognostic value of tumor markers in olfactory neuroblastoma (ONB).
  
  
  METHODS
  Seventeen patients with ONB (23 tumor specimens) were included. Each specimen was studied for bcl-2, p53, MIC-2 by immunohistochemistry and for N-myc by chromogenic in situ hybridization.
  
  
  RESULTS
  Twelve (70%) of 17 patients and 15 (65%) of 23 specimens showed positive reactivity for bcl-2. Of seven patients who were treated with neoadjuvant chemotherapy, one patient with diffuse bcl-2 expression achieved complete remission. Another patient without bcl-2 expression had no response to chemotherapy. Five patients who showed partial positivity achieved partial remission. Survival and bcl-2 expression tended to correlate, but it was not statistically significant (P = 0.06). All of the ONB specimens were negative for N-myc. Positive immunoreactivity for MIC-2 or p53 was found only in one specimen.
  
  
  CONCLUSIONS
  Bcl-2 expression was commonly found in ONB and the immunoreactivity for bcl-2 might predict response to neoadjuvant chemotherapy. In addition, Bcl-2 expression tended to be associated with worse survival.
authors.affiliation: Department of Otorhinolaryngology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
authors.forename: Jeong-Whun
authors.initials: JW
authors.lastname: Kim
authors.forename: Il Gyu
authors.initials: IG
authors.lastname: Kong
authors.forename: Chul Hee
authors.initials: CH
authors.lastname: Lee
authors.forename: Dong Young
authors.initials: DY
authors.lastname: Kim
authors.forename: Chae-Seo
authors.initials: CS
authors.lastname: Rhee
authors.forename: Yang-Gi
authors.initials: YG
authors.lastname: Min
authors.forename: Chul Woo
authors.initials: CW
authors.lastname: Kim
authors.forename: Jin-Haeng
authors.initials: JH
authors.lastname: Chung
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D015331:Cohort Studies; D018304:Esthesioneuroblastoma, Olfactory / Q000175:diagnosis / Q000378:metabolism* / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity; D020360:Neoadjuvant Therapy; D009669:Nose Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000628:therapy*; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D019253:Proto-Oncogene Proteins c-bcl-2